Latest Insider Transactions at Verve Therapeutics, Inc. (VERV)
This section provides a real-time view of insider transactions for Verve Therapeutics, Inc. (VERV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Verve Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Verve Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2021
|
Casdin Private Growth Equity Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
620,571
+50.0%
|
-
|
|
Jun 21
2021
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,495,571
+40.8%
|
-
|
|
Jun 21
2021
|
Krishna Yeshwant |
BUY
Conversion of derivative security
|
Indirect |
10,793,414
+36.34%
|
-
|
|
Jun 21
2021
|
Gv 2019 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,472,509
+29.51%
|
-
|
|
Jun 21
2021
|
Gv 2017 Gp, L.L.C. |
BUY
Conversion of derivative security
|
Indirect |
6,320,905
+50.0%
|
-
|
|
Jun 21
2021
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
350,000
+30.61%
|
$6,650,000
$19.0 P/Share
|
|
Jun 21
2021
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
443,265
+50.0%
|
-
|
|
Jun 21
2021
|
Logos Global Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
370,000
+50.0%
|
$7,030,000
$19.0 P/Share
|
|
Jun 21
2021
|
Logos Global Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
443,265
+50.0%
|
-
|
|
Jun 21
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
709,224
+50.0%
|
-
|
|
Jun 21
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
370,000
+28.54%
|
$7,030,000
$19.0 P/Share
|
|
Jun 21
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+0.61%
|
$47,500
$19.0 P/Share
|
|
Jun 21
2021
|
Andrew Bellinger Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$95,000
$19.0 P/Share
|
|
Jun 21
2021
|
Margaret Beaudoin Vice President, Finance |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$19,000
$19.0 P/Share
|